Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis

ObjectivesTo determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring to identify factors associated QTc prolongation occurring during treatment.MethodsData were collected from 35 who received treatment regimens containing MDR-TB May 2018 December 2020. Blood samples collected, concentrations measured using high-performance liquid chromatography–mass spectrometry.ResultsAfter completing 24-week course, 80.0% patients’ sputum cultures turned negative. The median time culture conversion was 75.5 days (interquartile range 52–126 days). mean 0.586 ± 0.288 µg/ml 0.205 0.145 at 16 weeks after discontinuation. Bedaquiline remained detectable 52 Combination clofazimine significantly increased cardiac prolongation. When occurred, potassium levels decreased by 10.71% baseline, while sodium 1.07% baseline.ConclusionsGood outcomes obtained in MDR-TB. risk Serum electrolytes (potassium sodium) should be regularly bedaquiline.